EDX Medical Group plc (AQSE: EDX), a developer of digital diagnostic products and services supporting personalised treatments for cancer, cardiovascular disease and infectious diseases, announced on Monday that it has signed a memorandum of understanding with UK independent healthcare group Spire Healthcare Group plc (LSE: SPI) to explore collaborative opportunities in diagnostic technologies and patient testing services across the UK.

The agreement will see both companies promote current and future clinical offerings, develop innovative patient referral pathways and create personalised healthcare and wellbeing propositions. The partnership aims to improve patient outcomes and enhance delivery of independent healthcare services in a cost-effective manner.

EDX Medical, founded by Professor Sir Christopher Evans and CEO Dr Mike Hudson, leverages digital and biological technologies to personalise treatment through early disease detection. The company operates facilities in Cambridge and Oxford and partners with organisations including Thermo Fisher EMEA Ltd.

Spire Healthcare, a FTSE 250 company, manages 38 hospitals and over 50 clinics across the UK, providing services to over 1.3 million patients in 2024. It is the largest private provider of knee and hip surgeries in the country and offers a range of NHS and private services under the Vita Health Group brand.